StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3043% below fair value
$1.50−0.02 (-1.32%)

Close on Nov 19, 2026Market cap $12.37MP/E –Yield –

Lipocine free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Lipocine's free cash flow for the twelve months ending Dec 31, 2024 was -$1.31M. For fiscal 2024 it was -$1.31M. The highest annual figure on record is -$1.31M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$1.31M–
FY2023Dec 31, 2023-$11.88M–
FY2022Dec 31, 2022-$12.10M–
FY2021Dec 31, 2021-$4.42M–
FY2018Dec 31, 2018-$12.08M–
FY2017Dec 31, 2017-$16.70M–
FY2016Dec 31, 2016-$18.34M–
FY2015Dec 31, 2015-$15.38M–
FY2014Dec 31, 2014-$17.36M–
FY2013Dec 31, 2013-$8.59M–
FY2012Dec 31, 2012-$3.19M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$1.69M–
Q4 FY2023Dec 31, 2023-$2.03M–
Q3 FY2023Sep 30, 2023-$2.61M–
Q2 FY2023Jun 30, 2023-$3.31M–
Q1 FY2023Mar 31, 2023-$3.93M–
Q4 FY2022Dec 31, 2022-$1.94M–
Q3 FY2022Sep 30, 2022-$3.20M–
Q2 FY2022Jun 30, 2022-$3.06M–
Q1 FY2022Mar 31, 2022-$3.91M–
Q4 FY2017Dec 31, 2017-$4.30M–
Q3 FY2017Sep 30, 2017-$4.57M–
Q2 FY2017Jun 30, 2017-$4.70M–
Q1 FY2017Mar 31, 2017-$3.14M–
Q4 FY2016Dec 31, 2016-$2.55M–
Q3 FY2016Sep 30, 2016-$4.05M–

More Lipocine figures

See a number that looks wrong?